Skip to content
Review Open access

Intratumoral microbiota: implications for colorectal cancer pathogenesis and therapy

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 127 references
Medicine

TL;DR

This review systematically summarizes the latest advances in understanding the relationship between intratumoral microbiota and CRC, critically appraises the strength of evidence across different hierarchical levels, evaluates the consistency and controversies surrounding major mechanistic hypotheses, and addresses methodological challenges inherent to low-biomass microbiome research.

Abstract

CRC is the third most prevalent malignancy worldwide and the second leading cause of cancer-related mortality. According to GLOBOCAN 2022 estimates, approximately 1.93 million new CRC cases and 900,000 CRC-related deaths occur annually worldwide. Incidence rates continue to rise in developing countries, driven by the westernization of dietary patterns, sedentary lifestyles, and increasing obesity prevalence, with a notable trend toward younger-onset disease. In recent years, mounting evidence has implicated the microbiota as a critical contributor to CRC initiation and progression. Distinct from the fecal microbiome, the intratumoral microbiome constitutes an independent, low-biomass microbial community predominantly composed of bacteria, with additional fungal, viral, and archaeal components. Microbial communities within the TME promote CRC development and progression by modulating host immune responses, metabolic pathways, and tumor cell proliferation and metastasis. Fusobacterium nucleatum, ETBF, polyketide synthase genotoxicity island-harboring Escherichia coli and Parvimonas micra represent the most well-substantiated candidate oncomicrobes, whose carcinogenic activities involve multiple intertwined pathways, including chronic inflammation, genotoxic DNA damage, immune evasion, metabolic reprogramming, and non-coding RNA regulation. Furthermore, intratumoral microbiota may serve as early diagnostic biomarkers for CRC, offer novel therapeutic targets, and provide potential biological rationale for prognostic prediction. Microbiome-based diagnostic biomarkers, such as multi-bacterial fecal/tissue panels, have demonstrated sensitivity comparable to or superior to the fecal immunochemical test in select retrospective cohorts; however, large-scale, multicenter, prospective validation remains necessary. Strategies targeting intratumoral bacteria — including antibiotics, bacteriophages, phage-guided nanocarriers, and FMT — remain predominantly in the preclinical stage. Although phase I/II trials of FMT for immunotherapy sensitization have yielded encouraging results, small sample sizes and substantial heterogeneity preclude its near-term adoption as a standard-of-care recommendation. This review systematically summarizes the latest advances in understanding the relationship between intratumoral microbiota and CRC, critically appraises the strength of evidence across different hierarchical levels, evaluates the consistency and controversies surrounding major mechanistic hypotheses, addresses methodological challenges inherent to low-biomass microbiome research, and discusses the translational potential in CRC diagnosis, therapy, and prognostic prediction.

Read PDF

Similar papers

Review Open access Jan 2026

Intratumoral Microbiome–Tumor Microenvironment Crosstalk in Breast Cancer Aggressiveness

Breast cancer (BC) remains the most common malignancy among women worldwide, with incidence and mortality rates continuing to rise. Alongside tumor heterogeneity and diverse clinical outcomes, increasing attention has been directed toward the role of the intratumoral microbiome as a regulator of breast tumorigenesis. R...

O. Mushii, Ye Lukianova, V. Bazas · 0 citations
Review Open access Nov 2026

The Gut Microbiome in Gastrointestinal Cancer: Unravelling the Hidden Drivers of Tumorigenesis and Therapeutic Response

Gastrointestinal (GI) cancers represent 26% of all cancer cases worldwide and are responsible for 35% of cancer deaths. These types of cancer have significant clinical challenges due to late detection and treatment resistance. The gut microbiome is a complex and adaptable ecosystem crucial for metabolism, intestinal ba...

V. Dudeja, Dhanisha Sulekha Suresh, Suryansh Suryansh et al. · 0 citations
Review Open access Oct 2026

The Gut Microbiota–Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation

This review critically examines emerging microbiome-directed strategies, including fecal microbiota transplantation, next-generation probiotics, defined bacterial consortia, dietary and perioperative interventions, postbiotics, and bacteriophage-based approaches, as potential means of modifying immune resistance in MSS...

Izabela Siemińska · 0 citations
Review Open access Oct 2026

Intratumoral Microbiota in Fueling Cancer and Steering Treatment Response

Microorganisms within tumors, also known as intratumoral microbiota, actively shape the tumor microenvironment (TME), influencing cancer progression and treatment response. Research has therefore expanded beyond the gut microbiota to intratumoral bacterial and fungal communities. Advances in low‐biomass sequencing, con...

Min-Hui Xu, Jie Yu, Ying Chen et al. · 0 citations
Review Open access Oct 2026

Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential

Esophageal cancer (EC) is a highly prevalent and aggressive gastrointestinal malignancy. Late diagnosis and heterogeneous responses to chemoradiotherapy and immune checkpoint inhibitor (ICI) therapies severely challenge clinical management. Accumulating evidence suggests that gut microbiota dysbiosis influences esophag...

Yong-Hao Li, Lu Zhou, Rui-Xue Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.